News
Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.
Left bundle branch block may serve as an important indicator for asymptomatic individuals predisposed to heart failure.
Key Points GAAP revenue surged to $66.8 million in Q2 2025, driven by recognition of one-time license and milestone payments, exceeding analyst estimates by 3,065.9% (GAAP). GAAP loss per share ...
US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the ...
The antiseizure medication pregabalin, which is commonly prescribed for noncancer pain, has been linked to an increased risk ...
Early symptoms like fatigue, breathlessness, swelling mimic common heart issues, causing cardiac amyloidosis to go undetected ...
A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...
An anti-hazing network honors a UVA leader, the American Heart Association lauds UVA Health for heart and stroke care, and ...
CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ...
A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...
According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...
Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results